# Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease?

> **NCT03104725** · PHASE1 · TERMINATED · sponsor: **National Institute of Neurological Disorders and Stroke (NINDS)** · enrollment: 6 (actual)

## Conditions studied

- Parkinson Disease
- Cerebrospinal Fluid

## Interventions

- **DRUG:** N-Acetylcysteine
- **PROCEDURE:** Lumbar Puncture
- **RADIATION:** Fluoroscopy

## Key facts

- **NCT ID:** NCT03104725
- **Lead sponsor:** National Institute of Neurological Disorders and Stroke (NINDS)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-09-25
- **Primary completion:** 2020-02-27
- **Final completion:** 2020-02-27
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Difficulty with recruitment and participant accrual due to study eligibility criteria and required study procedures (e.g., multiple lumbar punctures).
- **Last updated:** 2021-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03104725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03104725, "Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease?". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03104725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*